

Plasmodium falciparum, Strain W2

Catalog No. MRA-157

This reagent is the tangible property of the U.S. Government.

Product Description:

Plasmodium falciparum (*P. falciparum*), strain W2 was cloned from the Indochina III/CDC isolate originally derived from a Laotian patient who failed chloroquine therapy. *P. falciparum*, strain W2 is reported to be resistant to chloroquine and susceptible to mefloquine.

Lot: 63999676¹

Manufacturing Date: 08FEB2016

TEST	SPECIFICATIONS	RESULTS
Identification by Giemsa Stain Microscopy^{2,3}	Blood-stage parasites present	Blood-stage parasites present
Antimalarial Susceptibility Profile (<i>in vitro</i>)² Half-maximal Inhibitory Concentration (IC ₅₀) by SYBR green I [®] drug sensitivity assay ⁴ Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine	Report results Report results Report results Report results Report results Report results	60.0 ± 1.4 nM 4.4 ± 0.1 nM 84.0 ± 1.9 nM 1225 ± 56.4 nM 22120 ± 1529.2 nM 580700 ± 80482 nM
Genotypic Analysis² Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 800 base pairs)	Consistent with <i>P. falciparum</i>	Consistent with <i>P. falciparum</i> (Figure 1)
Functional Activity by PCR Amplification² MSP2 PCR amplicon analysis ⁵	~ 600 to 900 base pair amplicon	~ 800 base pair amplicon
Level of Parasitemia Pre-freeze ^{6,7} Ring-stage parasitemia Total parasitemia Post-freeze ^{2,8} Ring-stage parasitemia Total parasitemia	Report results ≥ 2% Report results ≥ 1%	3.07% 6.42% 1.63% 5.28%
Viability^{2,9}	Growth in infected red blood cells	Growth in infected red blood cells
Sterility (21-day incubation)² Harpo's HTYE broth, 37°C and 26°C, aerobic ¹⁰ Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth
Mycoplasma Contamination² DNA Detection by PCR	None detected	None detected

¹MRA-157 was produced by cultivation of BEI Resources MR-MRA-157 lot 58278719 in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 µg/mL hypoxanthine and 2.5 µg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂, 5% CO₂, 5% O₂) and monitored for parasitemia daily for 9 days. Every 1 to 2 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture as needed and monitored for hematocrit.

²Testing completed on vial post-freeze material

³Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 6 days.

⁴A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In *Methods in Malaria Research Sixth Edition*. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <https://www.beiresources.org/Publications/MethodsInMalariaResearch.aspx>].

⁵Primer sequences and conditions for PCR are available upon request.

⁶Testing completed on bulk material prior to vialing and freezing

⁷Parasitemia was determined after 9 days post infection by microscopic counts of Giemsa-stained blood smears.

⁸Parasitemia was determined after 6 days post infection by microscopic counts of Giemsa-stained blood smears.

⁹Viability was confirmed by examination of infected erythrocytes for parasitemia at 6 days post infection.

¹⁰Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

Figure 1: MRA-157 MSP2 Sequence

```
GTTACCTTTA ATATTAAAAA TGAAAGTAAA TATAGCAACA CATTCATAAA CAATGCTTAT AATATGAGTA TAAGGAGAAG
TATGGCAAAAT GAAGGTTCTA ATACTACTAG TGTAGGTGCA AATGCTCCAA ATGCTGATAC TATTGCTAGT GGAAGTCAAAA
GTAGTACAAA TAGTGCAAGT ACTAGTACTA CTAATAATGG AGAATCACAA ACTACTACTC CTACCGCTGC TGATACTATT
GCTAGTGGAA GTCAAAGGAG TACAAATAGT GCAAGTACTA GTACTACTAA TAATGGAGAA TCACAAACTA CTACTCCTAC
CGCTGCTGAT ACTATTGCTA GTGGAAGTCA AAGGAGTACA AATAGTGCAA GTACTAGTAC TACTAATAAT GGAGAATCAC
AACTACTAC TCCTACCGCT GCTGATACCC CTACTGTACT AGAAAGTAAT TCACCTTCAC CACCCATCAC TACTACAGAA
AGTTCAAGTT CTGGCAATGC ACCAAATAAA ACAGACGGTA AAGGAGAAGA GAGTGAAAAA CAAAATGAAT TAAATGAATC
AACTGAAGAA GGACCCAAAG CTCCACAAGA ACCTCAAACG GCAGAAAAATG AAAATCCTGC TGCACCAGAG AATAAAGGTA
CAGGACAACA TGGACATATG CATGGTTCTA GAAATAATCA TCCACAAAAT ACTTCTGATA GTCAAAAAGA ATGTACCGAT
GGTAACAAAG AAAACTGTGG AGCAGCAACA TCCCTCTTAA ATAACTCTAG TAATATTGCT TCAATAAATA AATTT
```

/Heather Couch/

Heather Couch

13 NOV 2019

Program Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

